ATP Synthase Inhibitor

Venturicidin B (Aabomycin A2) is a macrolide antibiotic isolated from Streptomyces sp., used as an antifungal agent, a potent inhibitor of the mitochondrial F0-ATP synthase complex.

KFP-H008 is an orally active potassium-competitive acid blocker. KFP-H008 inhibits gastric acid secretion through blocking H⁺-K⁺-ATPase. KFP-H008 reduces ethanol-induced gastric ulcer index and malonaldehyde as well as proinflammatory cytokine expression in vivo. KFP-H008 downregulates p-p38 MAPK and p65 NF-κB expression. KFP-H008 blocks histamine-stimulated acid secretion in rat and dog models. KFP-H008 can be studied in research on acid-related disease, such as ethanol-induced gastric ulcer and gastric epithelial cell damage.

LRPPRC-IN-1 is a LRPPRC inhibitor. LRPPRC-IN-1 exerts dual effects of inhibiting LRPPRC activity and inducing its degradation by binding to the RNA-binding domain of LRPPRC. LRPPRC-IN-1 downregulates the expression of mitochondrial OXPHOS complex subunits and ATP synthase, inhibits oxidative phosphorylation, reduces ATP production, suppresses the proliferation and colony formation of various cancer cells, and inhibits tumor growth in vivo. LRPPRC-IN-1 can be used in studies related to lung cancer, pancreatic cancer, breast cancer, esophageal cancer, colorectal cancer, lymphoma, melanoma, cervical cancer, ovarian cancer, and prostate cancer.

ATPase-IN-9 is an ATP synthase inhibitor. ATPase-IN-9 binds to the F₁ binding site of ATP synthase and inhibits its ATP hydrolytic activity. ATPase-IN-9 reduces intracellular ATP levels. ATPase-IN-9 can be used in research related to neurodegenerative diseases.

Ovothiol A disulfide is an inhibitor of light-triggered CF1 ATPase activity.

NSC799462 is a triazole inhibitor of p97 ATPase. NSC799462 inhibits p97 ATPase activity (IC₅₀ = 15 nM) by binding to a specific site on p97 and causing local changes in the p97 structure.

Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (K_i>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration).

ATP Synthesis-IN-4 is a mitochondria-targeted small-molecule ligand that inhibits ATP synthesis. ATP Synthesis-IN-4 binds to mtDNA G4s in melanoma cells, thereby inducing changes in mitochondrial metabolism and inhibiting cell proliferation. ATP Synthesis-IN-4 suppresses the translation of key mitochondrial respiratory chain proteins (CYTB, ATP8, COX1, COX3, ND2) in melanoma cells, downregulates the expression of OXPHOS complexes, activates the phosphorylation of AMPK, and induces metabolic reprogramming to upregulate glycolysis. ATP Synthesis-IN-4 is applicable to relevant research on melanoma.

LZ1 peptide acts as a Pyruvate kinase inhibitor, antimicrobial agent, and antimalarial agent. LZ1 peptide reduces ATP production and inhibits the malaria parasite Plasmodium falciparum. LZ1 peptide exhibits activity against Plasmodium berghei in mice and reduces parasitemia. LZ1 peptide shows favorable antimicrobial activity against pathogens associated with acne vulgaris. LZ1 peptide possesses anti-inflammatory effects. LZ1 peptide can be used in malaria-related research.

ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC₅₀=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL.

Antitumor agent-217 is a dual mitochondria-targeted anticancer agent. Antitumor agent-217 exhibits potent and selective antiproliferative activity against bladder cancer cell line J82 (IC₅₀ = 6.3 μM), and inhibits colony formation and migration of J82 cells. Antitumor agent-217 accumulates in mitochondria, alters mitochondrial morphology, reduces ATP production, increases ROS generation and decreases mitochondrial membrane potential. Antitumor agent-217 induces apoptosis (Apoptosis) and ferroptosis (Ferroptosis) in bladder cancer cells. Antitumor agent-217 can be used for the research of bladder cancer.

Tyrphostin AG17 is an orally active CDK2 inhibitor and EGFR tyrosine kinase antagonist. Tyrphostin AG17 reduces the levels of p21 and p16. Tyrphostin AG17 induces G1 phase cell cycle arrest, Apoptosis, mitochondrial dysfunction, decreased ATP levels, and inhibits DNA, RNA and protein synthesis, adipogenesis, and lipid synthesis. Tyrphostin AG17 inhibits fat accumulation, white adipose tissue hypertrophy, and alterations of glycogen and lipid inclusions in hepatocytes in obese mice without changing their serum biochemical parameters. Tyrphostin AG17 exhibits anticancer effects. Tyrphostin AG17 can be used in research related to immunoblastic lymphoma, leukemia, ovarian cancer, glioblastoma, colon cancer, breast cancer, melanoma, obesity and hepatic steatosis.

ATP Synthesis-IN-2 (Compound 5) is an antibacterial compound. ATP Synthesis-IN-2 is a potent ATP synthesis activity inhibitor with IC₅₀ against Pseudomonas aeruginosa (PA) Value of 0.7 μg/mL.

Parimifasor (Standard) is the analytical standard of Parimifasor (HY-109098). This product is intended for research and analytical applications. Parimifasor (LYC-30937) is an orally active agent for inflammatory bowel disease. Parimifasor targets F1F0-ATPase. Parimifasor acts on respiratory complex V, slows ATP production and induces Apoptosis. Parimifasor can be used in the research of inflammatory bowel disease.

Fenaminstrobin (SYP-1620) is a strobilurin Fungicide. Fenaminstrobin binds to cytochrome bc1 in the mitochondrial respiratory chain, thereby inhibiting ATP production. Fenaminstrobin exhibits acute toxicity to Daphnia magna. Fenaminstrobin effectively controls diseases such as Fusarium ear rot, downy mildew, rice blast and pear scab.

WEN05-03 is a EscN ATPase inhibitor. WEN05-03 blocks the active site of EscN ATPase and competitively inhibits its ATP hydrolysis activity. WEN05-03 completely blocks actin cluster formation, reduces actin pedestal formation, and decreases the toxicity of infected mammalian cells. WEN05-03 can be used in studies related to enteropathogenic E. coli (EPEC) infection.

ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC₅₀ value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection.

Abyssinone V is a prenylated flavonoid with predicted anti-viral activity. Abyssinone V can be isolated from the stem bark of Erythrina melanacantha. Abyssinone V possesses good pharmacodynamics properties. Abyssinone V is predicted to be antivirals including anti-herpes (HSV) agent, with mechanisms comprising inhibition of polymerase, ATPase and membrane integrity.

D-α-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of D-α-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling.

Gboxin (Standard) is the analytical standard of Gboxin (HY-111651). This product is intended for research and analytical applications. Gboxin is an oxidative phosphorylation (OXPHOS) inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity.